Clinical characteristics of coronavirus disease 2019 (COVID-19) in China : A systematic review and meta-analysis
Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved..
OBJECTIVE: To better inform efforts to treat and control the current outbreak with a comprehensive characterization of COVID-19.
METHODS: We searched PubMed, EMBASE, Web of Science, and CNKI (Chinese Database) for studies published as of March 2, 2020, and we searched references of identified articles. Studies were reviewed for methodological quality. A random-effects model was used to pool results. Heterogeneity was assessed using I2. Publication bias was assessed using Egger's test.
RESULTS: 43 studies involving 3600 patients were included. Among COVID-19 patients, fever (83.3% [95% CI 78.4-87.7]), cough (60.3% [54.2-66.3]), and fatigue (38.0% [29.8-46.5]) were the most common clinical symptoms. The most common laboratory abnormalities were elevated C-reactive protein (68.6% [58.2-78.2]), decreased lymphocyte count (57.4% [44.8-69.5]) and increased lactate dehydrogenase (51.6% [31.4-71.6]). Ground-glass opacities (80.0% [67.3-90.4]) and bilateral pneumonia (73.2% [63.4-82.1]) were the most frequently reported findings on computed tomography. The overall estimated proportion of severe cases and case-fatality rate (CFR) was 25.6% (17.4-34.9) and 3.6% (1.1-7.2), respectively. CFR and laboratory abnormalities were higher in severe cases, patients from Wuhan, and older patients, but CFR did not differ by gender.
CONCLUSIONS: The majority of COVID-19 cases are symptomatic with a moderate CFR. Patients living in Wuhan, older patients, and those with medical comorbidities tend to have more severe clinical symptoms and higher CFR.
| Errataetall: |
CommentIn: J Infect. 2020 Sep;81(3):452-482. - PMID 32504736 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:80 |
|---|---|
| Enthalten in: |
The Journal of infection - 80(2020), 6 vom: 02. Juni, Seite 656-665 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fu, Leiwen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 20.05.2020 Date Revised 03.11.2023 published: Print-Electronic CommentIn: J Infect. 2020 Sep;81(3):452-482. - PMID 32504736 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jinf.2020.03.041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM308681835 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM308681835 | ||
| 003 | DE-627 | ||
| 005 | 20231225132242.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jinf.2020.03.041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1028.xml |
| 035 | |a (DE-627)NLM308681835 | ||
| 035 | |a (NLM)32283155 | ||
| 035 | |a (PII)S0163-4453(20)30170-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fu, Leiwen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical characteristics of coronavirus disease 2019 (COVID-19) in China |b A systematic review and meta-analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.05.2020 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: J Infect. 2020 Sep;81(3):452-482. - PMID 32504736 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 The British Infection Association. Published by Elsevier Ltd. All rights reserved. | ||
| 520 | |a OBJECTIVE: To better inform efforts to treat and control the current outbreak with a comprehensive characterization of COVID-19 | ||
| 520 | |a METHODS: We searched PubMed, EMBASE, Web of Science, and CNKI (Chinese Database) for studies published as of March 2, 2020, and we searched references of identified articles. Studies were reviewed for methodological quality. A random-effects model was used to pool results. Heterogeneity was assessed using I2. Publication bias was assessed using Egger's test | ||
| 520 | |a RESULTS: 43 studies involving 3600 patients were included. Among COVID-19 patients, fever (83.3% [95% CI 78.4-87.7]), cough (60.3% [54.2-66.3]), and fatigue (38.0% [29.8-46.5]) were the most common clinical symptoms. The most common laboratory abnormalities were elevated C-reactive protein (68.6% [58.2-78.2]), decreased lymphocyte count (57.4% [44.8-69.5]) and increased lactate dehydrogenase (51.6% [31.4-71.6]). Ground-glass opacities (80.0% [67.3-90.4]) and bilateral pneumonia (73.2% [63.4-82.1]) were the most frequently reported findings on computed tomography. The overall estimated proportion of severe cases and case-fatality rate (CFR) was 25.6% (17.4-34.9) and 3.6% (1.1-7.2), respectively. CFR and laboratory abnormalities were higher in severe cases, patients from Wuhan, and older patients, but CFR did not differ by gender | ||
| 520 | |a CONCLUSIONS: The majority of COVID-19 cases are symptomatic with a moderate CFR. Patients living in Wuhan, older patients, and those with medical comorbidities tend to have more severe clinical symptoms and higher CFR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical characteristics | |
| 650 | 4 | |a Meta-analysis | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Wang, Bingyi |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Tanwei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaoting |e verfasserin |4 aut | |
| 700 | 1 | |a Ao, Yunlong |e verfasserin |4 aut | |
| 700 | 1 | |a Fitzpatrick, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Peiyang |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Yiguo |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yi-Fan |e verfasserin |4 aut | |
| 700 | 1 | |a Duan, Qibin |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Ganfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Fan, Song |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Anping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Yuewei |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Bowen |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Weiping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Du, Xiangjun |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Linghua |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Yuelong |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Huachun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infection |d 1982 |g 80(2020), 6 vom: 02. Juni, Seite 656-665 |w (DE-627)NLM012791822 |x 1532-2742 |7 nnns |
| 773 | 1 | 8 | |g volume:80 |g year:2020 |g number:6 |g day:02 |g month:06 |g pages:656-665 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jinf.2020.03.041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 80 |j 2020 |e 6 |b 02 |c 06 |h 656-665 | ||